# Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

> **NCT07018427** · — · ACTIVE_NOT_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 70 (actual)

## Conditions studied

- Breast Neoplasms
- Triple Negative Breast Cancer
- HR+, HER2-, Advanced Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan Monotherapy or Combination Therapy

## Key facts

- **NCT ID:** NCT07018427
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018427, "Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07018427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*